Status | Study |
Active, not recruiting |
Study Name: Initial Treatment With Bevacizumab in Choroidal Neovascularization Associated to High Myopia Condition: Choroidal Subfoveal/Juxtafoveal Neovascularization in High Myopia Date: 2012-10-25 Interventions: Drug: Bevazizumab intravitreal injection Intravitreal injection of bevacizumab |
Completed |
Study Name: Treatment of Corneal Neovascularization With Topical Pazopanib Condition: Corneal Neovascularization Date: 2010-11-22 Interventions: Drug: Pazopanib (5mg/ml) Topical pazopanib, 4 times per day for 3 weeks |
Recruiting |
Study Name: Ranibizumab for Myopic Neovascularization Condition: Myopic Choroidal Neovascularization Date: 2010-11-20 Interventions: Drug: ranibizumab injection Ranibizumab intravitreal injection of 0,5 mg ( 0.05mL) |
Completed |
Study Name: Ranibizumab for the Treatment of Choroidal Neovascularisation (CNV) Secondary to Pathological Myopia (PM): an Individualized Regimen Condition: Choroidal Neovascularisation Date: 2009-12-21 Interventions: Drug: ranibizumab 0.5mg |
Completed |
Study Name: Bevacizumab for the Treatment of Corneal Neovascularization Condition: Corneal Neovascularization Date: 2009-10-08 Interventions: Drug: Bevacizumab Topical 10 mg/cc or subconjunctival 2.5 mg/0.1cc |
Terminated |
Study Name: Topical IL-1-Ra for Treatment of Corneal Neovascularization Condition: Corneal Neovascularization Date: 2009-06-04 Interventions: Drug: Placebo Custom eye drop |
Completed |
Study Name: Bevacizumab Intravitreal for Myopic Choroidal Neovascularization Condition: Myopic Choroidal Neovascularization Date: 2008-11-24 Interventions: Drug: Injection Intravitreal injection of 1.25 mg bevacizumab |
Completed |
Study Name: The Effect of Bevacizumab on Corneal Neovascularization Condition: Corneal Neovascularization Date: 2008-11-22 Interventions: Drug: Bevacizumab subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 mon |
Completed |
Study Name: Ranibizumab for the Inhibition of Neovascularization in the Cornea Following Corneal Transplant Surgery Condition: Corneal Neovascularization Date: 2008-10-07 Interventions: Drug: Ranibizumab 0.5mg subconjunctival dose of ranibizumab 3 days prior to corneal transplantation and |
Completed |
Study Name: Effectiveness and Safety of Topical Ranibizumab for Treatment of Corneal Neovascularization (NV) Condition: Corneal Neovascularization Date: 2008-05-19 Interventions: Drug: Ranibizumab 10 Patients will receive treatment (Ranibizumab) |